GLP-1 Savings Cards: Wegovy, Zepbound, Mounjaro, and Ozempic (2026 Guide)

The list price of a GLP-1 drug in 2026 is somewhere between $900 and $1,350 per month, depending on which drug and which pharmacy. The average commercially insured patient pays around $25 per month. The gap between those two numbers is closed, in most cases, by a manufacturer savings card. This guide covers how every major GLP-1 card works, who qualifies, what the annual limits are, and the specific situations where the card fails you — and what to do instead.

What a manufacturer savings card actually is

A manufacturer savings card is a copay assistance program operated directly by the pharmaceutical company. It functions as a secondary payer: your commercial insurance pays its portion first, and the savings card covers some or all of the remaining patient cost, subject to a per-fill and annual maximum.

The cards are not coupons in the traditional sense. They have BIN, PCN, and group codes — the same technical fields used by insurance — and are processed through the pharmacy benefit system like a second insurance plan. Enrolling takes five minutes online. Activation happens automatically at checkout when the pharmacy runs both your insurance and the card together.

These programs exist because GLP-1 drugs carry list prices that are difficult for most commercially insured patients to absorb even after insurance, and manufacturers use the cards to reduce access friction. They are not charitable programs; they are commercial pricing tools, and their terms change every calendar year.

The four cards compared

The table below reflects current program terms as of May 2026. All programs exclude government-funded payers.

Notes on supply quantities. All four cards allow 2- and 3-month supplies. The per-fill cap scales proportionally: a 3-month Wegovy or Ozempic fill carries a $300 maximum savings; a 3-month Zepbound fill carries a $300 maximum savings; a 3-month Mounjaro fill carries a $450 maximum savings. Filling a 90-day supply at once is not the same as three separate monthly fills — it counts as one fill toward your annual limit.

Ozempic note. Ozempic is FDA-approved for type 2 diabetes management, not weight loss. The savings card is therefore issued under the diabetes indication. Patients prescribed Ozempic for weight-related off-label use may encounter insurance formulary issues independent of the card. See Ozempic vs Wegovy cost considerations for more detail.

Who qualifies — and who is excluded

Qualifying patients

To use any of these cards you must:

• Hold a valid prescription for that specific branded drug
• Have commercial (private) insurance — including employer-sponsored plans, ACA marketplace plans, and private individual plans
• Be 18 years of age or older and a US resident
• Not be enrolled in any government-funded insurance program

That last requirement is the single most common point of confusion.

The government-payer exclusion

Federal anti-kickback law prohibits pharmaceutical manufacturers from offering copay subsidies to patients insured through government-funded programs. The relevant programs are:

• Medicare Part D (the prescription drug benefit)
• Medicare Advantage (even when administered by private insurers)
• Medigap (supplemental Medicare coverage)
• Medicaid
• TRICARE (military)
• VA health benefits
• Department of Defense coverage
• Any state-funded pharmaceutical assistance program

The exclusion applies to the funding source, not the insurance company's name. A patient enrolled in a Medicare Advantage plan administered by United Healthcare or Aetna is still ineligible, because the underlying funding is federal.

This surprises a significant number of patients. Many readers of GLP-1 forums describe going to the pharmacy, presenting a savings card they enrolled in online, and being told it cannot be processed because their plan is flagged as a government payer. The card enrollment process does not always catch this upfront — it asks self-reported eligibility questions, and some patients genuinely do not know whether their plan is Medicare Advantage or a standard commercial plan.

If you have Medicare coverage of any kind, skip to the Medicare GLP-1 coverage overview for the alternatives that actually apply to you, including the CMS Medicare GLP-1 Bridge program launching July 1, 2026.

Accumulator adjustment programs

A separate eligibility trap does not exclude you from the card entirely but significantly reduces its value. Many large commercial insurance plans use accumulator adjustment programs (sometimes called copay maximizers). Under these arrangements, the insurer does not count manufacturer copay assistance toward your deductible or annual out-of-pocket maximum.

The practical result: you pay $25 per fill via the savings card, but your deductible continues to accrue as though you paid nothing — because from the insurer's perspective, you did not pay. Once the savings card hits its annual cap, you face full cost-sharing until you independently meet your deductible. Patients on high-deductible health plans are most exposed.

Call your insurer before enrolling. Ask specifically: "Does my plan use an accumulator adjustment program or copay maximizer for specialty drugs?" If yes, calculate whether the $1,200–$1,950 annual card benefit is worth the deductible gap it may create.

How to activate each card: step by step

The enrollment process is nearly identical across all four drugs. Steps differ only in the URL and program name.

Wegovy (Novo Nordisk)

1. Visit novocare.com or text SAVE to 83757
2. Answer the eligibility questionnaire (takes roughly two minutes)
3. Receive your card details: BIN 004682, PCN ADV, and a group code — save these on your phone
4. Present both your insurance card and the savings card details to your pharmacist at the time of fill
5. The pharmacy runs insurance first, then applies the card to the remaining balance

Enrollment tip. The Wegovy savings card can be enrolled in before or at the time of your first fill. It cannot be applied retroactively to fills already processed.

Ozempic (Novo Nordisk)

The process is identical to Wegovy, using the NovoCare diabetes savings card. Enroll at novocare.com or call 1-877-304-6855. The BIN/PCN/Group codes differ from the Wegovy card — do not swap them.

Zepbound (Eli Lilly)

1. Visit zepbound.lilly.com/savings
2. Select the "Covered benefit" tier if your insurance covers Zepbound, or the "Not covered" tier if your plan excludes it
3. Complete the eligibility form and receive card details
4. Take the BIN, PCN, and group number to your pharmacy; Lilly also provides a printable card

Covered vs. not-covered tiers. If your insurance covers Zepbound at any tier, you use the $25 covered-benefit card. If your insurance does not cover Zepbound, Lilly routes you to the non-covered benefit program, which starts at $499/month for the single-dose pen — significantly higher but still below the full list price. Alternatively, patients with no coverage can access LillyDirect for Zepbound, which offers the self-pay vial program starting at $299/month.

Mounjaro (Eli Lilly)

1. Visit mounjaro.lilly.com/savings-resources or contact Lilly Support at 1-800-545-5979
2. Select the savings card option and complete the eligibility form
3. Receive your card codes and bring them to the pharmacy

The Mounjaro card covers up to 13 fills per calendar year, expiring December 31, 2026.

What you actually pay: coverage scenarios

The card's value depends entirely on what your insurance leaves as your share. Here are the three most common situations:

Scenario 1 — Drug is on formulary, standard copay. Your plan covers Wegovy or Zepbound at Tier 3 (specialty tier), and your normal copay is $175. The savings card covers $150 of that, and you pay $25. This is the intended use case.

Scenario 2 — Drug is covered but requires prior authorization. The card does not help with the PA process itself. Until your insurer approves the prior auth, most pharmacies will not process the prescription at all. Once approved, the card applies normally to your copay.

Scenario 3 — Drug is not covered by your plan. You are shifted to the non-covered tier of the savings card. For Wegovy, this means Novo Nordisk's self-pay program — either the NovoCare flat rate ($349/month) or, for new patients, the introductory $199/month for the first two fills at starter doses. For Zepbound, you access the non-covered savings card tier ($499/month for the pen) or LillyDirect's self-pay vial option ($299–$449/month by dose). Neither of these is a $25/month outcome. Full detail at Wegovy without insurance and Zepbound cost guide.

The five pitfalls that catch patients off guard

1. The annual savings cap

Each card carries an annual maximum. Once you have used the full benefit — roughly $1,200 for Wegovy and Ozempic, $1,300 for Zepbound, and $1,950 for Mounjaro — the card stops covering your copay for the remainder of the calendar year. At $100/month maximum savings, most patients will exhaust a Wegovy or Zepbound card between October and December. The cap resets January 1.

Patients who reach the cap mid-year face their full insurance cost-sharing until the new card year begins — which can be several hundred dollars per fill on a specialty-tier plan. Planning for this: some patients fill a 90-day supply early in Q4 to maximize remaining card benefit before the annual cutoff, rather than taking monthly fills that exhaust the last few months at full price.

2. Tier changes and formulary shifts

Commercial insurance plans update their drug formularies annually during open enrollment (effective January 1). A drug that was covered at Tier 3 in 2025 may move to Tier 4 or be excluded entirely in 2026, or vice versa. When a drug moves from covered to excluded, your card tier changes with it. Patients who enrolled in the $25/month covered-benefit card in November may discover in January that their plan no longer covers the drug — and they now owe $499 or more, not $25.

Check your plan's formulary each November during open enrollment. Drug coverage for weight management has shifted repeatedly as payers respond to cost pressures and new clinical evidence.

3. The Medicare confusion

Patients with employer-sponsored insurance who turn 65 and become Medicare-eligible mid-year often assume they can keep using their savings card. Under federal anti-kickback rules, the moment a patient is eligible for Medicare — even if still enrolled in a commercial plan — they may be considered ineligible for manufacturer copay programs. This applies even to retirees on employer group plans that coordinate with Medicare. If you are within a year of Medicare eligibility, call your prescriber's billing team before assuming the card will continue to work.

4. The card can be changed or discontinued at any time

Both Novo Nordisk and Eli Lilly include explicit language in their savings card terms noting that the programs can be modified, reduced, or discontinued without notice. This has happened before: Novo Nordisk modified Wegovy's savings program terms in early 2025. The $25/month outcome is real for eligible patients today. It is not guaranteed indefinitely.

5. Not re-enrolling at the annual reset

Both Lilly cards expire December 31, 2026. If you do not re-enroll for 2027 when new program terms are published (typically in November–December), your card will fail to process at the pharmacy on your January fill. Set a calendar reminder for mid-November each year.

When the savings card does not help: alternatives

If you are not commercially insured, or if your savings card benefit runs out, two direct-from-manufacturer programs offer the best available prices:

NovoCare Pharmacy (Wegovy and Ozempic): Novo Nordisk's own pharmacy charges $349/month flat across all Wegovy injection doses, with an introductory $199/month for the first two fills at the 0.25 mg and 0.5 mg starter doses (limited-time offer, valid through June 30, 2026). No savings card required. Full enrollment process at NovoCare Wegovy enrollment guide.

LillyDirect (Zepbound): Eli Lilly's direct-pay program for the Zepbound vial and KwikPen starts at $299/month for the 2.5 mg dose and scales to $449/month for the highest dose. This price is the same for vials and pens since Lilly unified pricing in February 2026. No insurance or savings card needed. See LillyDirect Zepbound enrollment guide.

Both NovoCare and LillyDirect are legitimate, FDA-regulated dispensing channels operated directly by the manufacturers. They are the correct fallback when savings cards are not an option.

Terms current as of May 28, 2026. Manufacturer savings programs change annually and sometimes mid-year. Verify current terms directly at novocare.com and lilly.com before enrolling. Pricing claims on this page are sourced to manufacturer websites and dated to the publication date above; [email protected] for update requests.